Gene therapy developer and manufacturer Forge Biologics has agreed to be acquired by Ajinomoto Co the companies announced Monday. The Japanese multinational food and biotechnology company will pay 554 million to Forge shareholders. On a cashfree and debtfree basis the deal values Forge at 620 million Ajinomoto said